Citalopram-induced Raynaud's phenomenon

Rheumatology International

Volumn 27, Issue 6, 2007, Pages 599-601

  Peiro A M ^a   Margarit, C ^a   Torra, M ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLONAZEPAM; CLORAZEPATE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; LORMETAZEPAM; OLANZAPINE; PAROXETINE; SERTRALINE; TOPIRAMATE; TRAMADOL; ZOPICLONE;

ADULT; ANXIETY DISORDER; ARTICLE; CASE REPORT; CYANOSIS; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTROPHY; ERYTHEMA; FEMALE; HUMAN; INSOMNIA; NEUROPATHIC PAIN; PRIORITY JOURNAL; RAYNAUD PHENOMENON;

ADULT; ANALGESICS; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; HUMANS; NEURALGIA; RAYNAUD DISEASE; SEROTONIN UPTAKE INHIBITORS;

EID: 33947106610     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0254-9     Document Type: Article

References (15)

1. Kahaleh B, Matucci-Cerinic M (1995) Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 38:1-4
2. Herrick AL (2005) Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44:587-596
3. Buecking A, Rougemont E, Fabio Zullino D (2005) Treatment of Raynaud's phenomenon with escitalopram. Int J Neuropsychopharmacol 8:307-308
4. Rudnick A, Modai I, Zelikovski A (1997) Fluoxetine-induced Raynaud's phenomenon. Biol Psychiatry 41:1218-1221
5. Richard MA, Fiszenson F, Jreissati M, Jean Pastor MJ, Grob JJ (2001) Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases. Ann Dermatol Venereol 128:759-761
6. Coleiro B, Marshall SE, Denton CP et al (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40:1038-1043
7. Bolte MA, Avery D (1993) Case of fluoxetine-induced remission of Raynaud's phenomenon - a case report. Angiology 44:161-163
8. Garcia-Porrua C, Margarinos CC, Gonzalez-Gay MA (2004) Raynaud's phenomenon and serotonin reuptake inhibitors. J Rheumatol 31:2090
9. Bell C, Coupland N, Creamer P (1996) Digital infarction in a patient with Raynaud's phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report. Angiology 47:901-903
10. Bourgade B, Jonville-Bera AP, Le Gare C, Ferquel D, Autret-Leca E (1999) Raynaud's syndrome in a patient treated with milnacipran. Ann Pharmacother 33:1009-1010
11. Rey E, Cretel R, Pastor M-J, Durand J-M (2003) Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia. Rheumatology 42:601-602
12. Sunahara JF, Gora-Harper ML, Nash KS (1996) Possible erythromelalgia-like syndrome associated with nifedipine in a patient with Raynaud's phenomenon. Ann Pharmacother 30:484-486
13. Rudikoff D, Jaffe IA (1997) Erythromelalgia: response to serotonin reuptake inhibitors. J Am Acad Dermatol 37:281-283
14. Moiin A, Yashar SS, Sanchez JE, Yashar B (2002) Treatment of erythromelalgia with a serotonin/noradrenaline reuptake inhibitor. Br J Dermatol 146:336-337
15. Sanders-Bush E, Mayer SE (2001) 5-Hysroxytryptamine (serotonin): receptor agonist and antagonist. In: Hardman JG, Limbird LE, eds. Goodman&Gilman's. The pharmacological basis of therapeutics. 10th edn. McGraw Hill, New York